Skip to main content
PMC home page
Nature Portfolio logoLink to Nature Portfolio
. 2021 Dec 8;102(5):485–493. doi: 10.1038/s41374-021-00710-6

MiR-200c-3p targets SESN1 and represses the IL-6/AKT loop to prevent cholangiocyte activation and cholestatic liver fibrosis

Yongfeng Song 1,2, Melanie Tran 1, Li Wang 3, Dong-Ju Shin 1, Jianguo Wu 4,5,✉
PMCID: PMC9042705  NIHMSID: NIHMS1758522  PMID: 34880414

Abstract

Cholestasis causes ductular reaction in the liver where the reactive cholangiocytes not only proliferate but also gain a neuroendocrine-like phenotype, leading to inflammatory cell infiltration and extracellular matrix deposition and contributing to the development and progression of cholestatic liver fibrosis. This study aims to elucidate the role of miR-200c in cholestasis-induced biliary liver fibrosis and cholangiocyte activation. We found that miR-200c was extremely abundant in cholangiocytes but was reduced by cholestasis in a bile duct ligation (BDL) mouse model; miR-200c was also decreased by bile acids in vitro. Phenotypically, loss of miR-200c exacerbated cholestatic liver injury, including periductular fibrosis, intrahepatic inflammation, and biliary hyperplasia in both the BDL model and the 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) model. We identified sestrin 1 (SESN1) as a target of miR-200c. Sesn1−/−-BDL mice showed mitigation of cholestatic liver injury. On a molecular level, the pro-proliferative IL-6/AKT feedback loop was activated in Mir200c−/− livers but was inhibited in Sesn1−/− livers upon cholestasis in mice. Furthermore, rescuing expression of miR-200c by the adeno-associated virus serotype 8 ameliorated BDL-induced liver injury in Mir200c−/− mice. Taken together, this study demonstrates that miR-200c restrains the proliferative and neuroendocrine-like activation of cholangiocytes by targeting SESN1 and inhibiting the IL-6/AKT feedback loop to protect against cholestatic liver fibrosis. Our findings provide mechanistic insights regarding biliary liver fibrosis, which may help to reveal novel therapeutic targets for the treatment of cholestatic liver injury and liver fibrosis.

Subject terms: Mechanisms of disease, Experimental models of disease

Cholangiocytes are the primary targets of cholangiopathies. This study elucidates the role of miR-200c in maintaining cholangiocyte homeostasis making use of cell culture and mouse models of cholestasis. MiR-200c restrains the proliferative and neuroendocrine-like activation of cholangiocytes by targeting sestrin 1(SESN1) and inhibiting the IL-6/AKT feedback loop to prevent cholestatic liver injury. The findings provide critical mechanistic insights into biliary liver fibrosis and suggest miR-200c may be a novel therapeutic target of cholangiopathies.

Introduction

Cholestatic liver diseases arise from intrahepatic retention of cytotoxic bile acids (BAs) because of impaired bile formation and/or flow, accounting for a significant part of end-stage liver disease. Structural blockage, toxic substances, immunologic dysregulation, and congenital defects can be the etiology. BA-contributed injury to bile ducts and hepatocytes can lead to abnormal liver biochemistry, ductular reaction, biliary fibrosis, and disease progression to cirrhosis1. The activation and transdifferentiation of quiescent hepatic stellate cells (HSCs) into fibrogenic myofibroblasts are the key cellular events in liver fibrosis. HSCs increasingly express ACTA2 (actin alpha 2, smooth muscle; alias α-SMA) and other proteins (e.g., collagens) forming the connective tissue and synthesize and release tissue inhibitors of metalloproteinase (TIMP)-1 and -2. Despite these, a recognized common notion is that liver fibrosis is also impacted by other liver cell types and regulated by a broad spectrum of cytokines, chemokines, growth factors, and hormones2.

Cholangiopathies, such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are characterized by biliary fibrosis and cholangiocytes as their primary targets. Cholestasis undermines the normal function of biliary epithelia and activates cholangiocytes. Reactive cholangiocytes proliferate and gain a neuroendocrine-like phenotype, constituting a cholangio-compartment promoting ductular reaction and periductular fibrosis. Cholangiocytes play an essential role not only in sustaining biliary proliferation itself but also in immune responses and hepatic inflammation. Reactive cholangiocytes secrete a range of different proinflammatory cytokines and chemokines (e.g., IL-6), which mediate the crosstalk with other hepatic cell types3.

IL-6 is an inflammatory cytokine and involved in cholangiocyte proliferation4. Cholangiocytes not only express receptors but also release mediators influencing cell proliferation, e.g., IL-6, thus constituting an autocrine feedback loop to amplify the proliferative response in ductular reaction5,6. In cholangiocytes, IL-6 activates the MAPK (mitogen-activated protein kinase and the PI3K (phosphatidylinositol-3 kinase)/AKT pathways to promote proliferation7. A reciprocal activation between IL-6 and AKT has been noticed. IL-6 elicits AKT activation8, while AKT activation promotes IL-6 production9–11.

MicroRNAs (miRNAs) are a class of small and regulatory non-coding RNAs (ncRNAs) of 21–25 nucleotides in length and control gene expression by degrading target mRNAs or suppressing protein translation12. Over one-third of human genes are targets of conserved miRNAs, which are involved in various biological processes. Recent studies have discovered several miRNAs that are involved in the progression of cholestatic liver fibrosis13. The miR-200 family comprises 5 members: miR-200a, miR-200b, miR-200c, miR-141, and miR-429. Expression levels of miR-200a and miR-200b were increased during liver fibrosis in mice14 and in fatty liver disease in rats15. Moreover, upregulation of miR-200b stimulated proliferation and migration of HSCs via the PI3K/AKT signaling pathway16, whereas upregulation of miR-200a inhibited TGF-β1-induced HSCs activation and proliferation17, suggesting the functional complexity of miR-200 family. Despite these advances, limited information is available regarding the specific function of miR-200 family in cholangiocytes and cholestatic liver injury.

Sestrin 1 (SESN1), also known as PA26, is a member of the stress-responsive gene family. SESN1 is a p53-target gene and confers resistance to p53-induced oxidative stress through facilitating regeneration of peroxiredoxins18. Independently of their redox activity, SESN1 inhibits expression of mTOR, thus mediating its aging-related function19. However, the pathophysiological function of SESN1 in the liver remains undetermined.

This study aims at understanding the function of miR-200c in cholestatic liver fibrosis making use of gene knockout mice. We identified SESN1 as a novel target of miR-200c. We elucidated a new miR-200c/SESN1 regulatory axis contributing to IL-6/AKT-mediated cholangiocyte activation in the development of cholestatic liver fibrosis.

Materials and methods

Animals

The whole body Mir200c−/− mice on a mixed 129/C57 background were recently generated20. MiR-141, clustered with miR-200c, was also deleted due to technical difficulties when generating the strain. Sesn1−/− mice (C57BL/6 N) were purchased from the Jackson Laboratory (Stock No. 027566). Mice were fed a standard rodent chow diet (Harlan, No. 2018) with free access to water and housed in a temperature-controlled (23 °C), pathogen-free room with a 12-h light and 12-h dark cycle. In vivo experiments were performed on male mice at the age of 6 weeks unless stated otherwise (n = 5–10 mice/group). The treatment of mice with 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-supplemented diet and the bile duct ligation (BDL) surgery have been described previously21,22. For in vivo viral transduction, mice were injected via tail vein with the purified adeno-associated virus serotype 8 (AAV8) containing a liver-specific thyroxine-binding globulin (TBG) promoter driving miR-200c expression at 5 × 1010 virus particles per mouse23. All mice were sacrificed after overnight fasting unless otherwise indicated. Whole blood was collected, and serum was obtained by centrifugation (1,500 rpm, 15 min) and stored at −80 °C until analysis. Basic procedures to analyze serum biochemistry parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), and direct bilirubin (DBIL), were described previously24. The serum BA concentrations were measured with a Colorimetric Total Bile Acid Assay Kit (#STA-631, CELL BIOLABS, Inc). H&E, Masson Trichrome, Sirius Red, and immunohistochemistry (IHC) staining were performed. Five fields of view per slide per mouse liver were randomly taken under a microscope and quantified by ImageJ. The sample size is the number of mice in each experimental group, which was shown in figure legends and Supporting Information. Protocols for animal use were approved by the IACUC at the University of Connecticut.

Isolation of primary mouse hepatocytes, HSCs, Kupffer cells (KCs), and cholangiocytes

Primary mouse hepatocytes were isolated using a standard two-step collagenase digestion method as previously described25. Primary HSCs and KCs were isolated using Percoll gradient centrifugation method as previously described26. For cholangiocytes, the biliary tree was digested with collagenase, hyaluronidase, and bovine pancreas trypsin, filtered in a 70 μm cell strainer, and then purified by immunoaffinity separation as previously described27.

Other standard methods

Luciferase assays, mutagenesis, qPCR, Western blot (WB), and IHC were described previously24,28. For WB, equal amounts of protein from individual mouse liver in each group (n = 5–10/group) were pooled, and single or duplicate loadings were used. The bands were quantified using ImageJ and the relative expression was denoted. Primers and additional materials and methods were detailed in Supporting Information.

Statistical analysis

Data are shown as the mean ± standard error of the mean (SEM) and are representative of at least three independent experiments. Normal distribution of the data was examined using the Shapiro-Wilk test and data was log-transformed as necessary to obtain a normal distribution. Statistical analysis was carried out using the Student’s t-test between two groups and one-way ANOVA followed by Tukey’s post hoc test for multiple groups. P < 0.05 was considered statistically significant.

Results

BAs enhance cholangiocyte activation by diminishing expression of miR-200c

Among the primary mouse hepatic cells, cholangiocytes expressed 20 to 40 folds higher levels of miR-200c than HSCs and KCs. The expression level of miR-200c in cholangiocytes was about 800 folds higher than that in hepatocytes, implying its potential role in maintaining biliary homeostasis (Supporting Fig. 1A). The expression level of miR-200c was decreased by about 50% in cholangiocytes 1 week after BDL surgery. On the contrary, it was increased in hepatocytes by BDL (Fig. 1A and Supporting Fig. 1B).

Fig. 1. BAs decrease expression of miR-200c to promote IL-6-mediated cholangiocyte proliferation.

Fig. 1

Open in a new tab

A qPCR of the expression level of miR-200c in primary cells isolated from WT mouse livers 1 week after sham or BDL surgery. Data are shown as mean ± SEM (n = 5/group). *P < 0.05 & **P < 0.01 vs. sham. B qPCR of the expression level of miR-200c in mouse large cholangiocytes (MLC) and human cholangiocarcinoma cells (HuCCT-1). MLC and HuCCT-1 cells were treated with CA (100 µM), TCA (100 µM), CDCA (100 µM), UDCA (100 µM), or LCA (10 µM) for 24 h. Data are shown as mean ± SEM. *P < 0.05 & **P < 0.01 vs. DMSO. C Transient transfection to determine luciferase reporter activity of miR-200c promoter regulated by CA. Data are shown as mean ± SEM. *P < 0.05 & **P < 0.01 vs. DMSO. D Cell proliferation was determined by BrdU incorporation. MLC cells were transfected with control (con) or miR-200c plasmid for 24 h, followed by the treatment with DMSO or CA for 48 h in the presence of BrdU. Data are shown as mean ± SEM. **P < 0.01 vs. DMSO, ##P < 0.01 vs. con-CA. E ELISA of the expression level of IL-6. MLC cells were transfected with control miRNA, miR-200c, or miR-200c inhibitor (anti-miR-200c), and then treated with DMSO or CA (100 µM) for 48 h. The secreted form of IL-6 was determined by ELISA. Data are shown as mean ± SEM. *P < 0.05 & **P < 0.01 CA vs. DMSO; ##P < 0.01 vs. control-DMSO; &&P < 0.01 vs. control-CA.

BDL results in BA accumulation in the liver, disrupts epithelial tight junctions and barrier integrity of bile ducts, and leads to direct infiltration of hepatic cells by BAs. The BA composition and dynamics in BDL-mice have been elucidated before29. Although some secondary BAs, e.g., taurochenodeoxycholic acid (TDCA) and lithocholic acid (LCA), show decreasing trends, most of the hepatic BAs increase as early as 6 h post-BDL and then subside in BDL-mice29. BAs in livers of BDL-mice gradually become more hydrophilic (from hydrophilic to hydrophobic: muricholic acid (MCA) > ursodeoxycholic acid (UDCA) > cholic acid (CA) > chenodeoxycholic acid (CDCA) > deoxycholic acid (DCA) > LCA; taurine-conjugated > glycine-conjugated > unconjugated)30–32. Rather than cause direct toxicity, BAs may act as inflammagens after BDL in mice29. Numerous in vitro studies have investigated the effect of BAs on different liver cell types27,33,34. How BAs regulate expression of miR-200c remains undetermined. We examined the expression level of miR-200c in cholangiocytes exposed to several BAs, which represent distinct hydrophilicity and are the major BA species in both mouse and human BA pools, although the level of LCA is very low in mice30. As the expression level of miR-200c was much higher in MLC and human HuCCT-1 than MSC cells (Supporting Fig. 1C), we used MLC and HuCCT-1 for further studies. Expression of miR-200c was reduced in both MLC and HuCCT-1 cells treated with several BAs, including CA, taurocholic acid (TCA), CDCA and/or UDCA, for 24 h and further decreased in MLC cells exposed to CA for 48 h (Fig. 1B and Supporting Fig. 1D). Luciferase assays using reporters containing upstream sequences (−3 kb and −922 bp) of human pri-miR-200c demonstrated that the reporter activity was dose-dependently inhibited by CA (Fig. 1C), suggesting a suppressive effect of CA on the transcription of miR-200c. We predicted the transcription factors (TFs) that potentially bind miR-200c promoter (the above −922 bp sequence) using the online tool ALGGEN-PROMO. In addition to Sp1 known to activate transcription of miR-200c35, among the many predicted TFs, HNF1A’s binding site has a significant score and is conserved in mice and humans. CA impaired the activation of miR-200c promoter by Sp1, while promoted the inhibition of miR-200c promoter by HNF1A, suggesting CA might non-specifically affect the interaction between TFs and miR-200c promoter (Supporting Fig. 1E). Although TCA increases the level of S1PR2 mRNA in MLC cells27, we did not find significant changes of expression of mRNAs of BA receptors, including TGR5, S1PR2, VDR, FXR, and PXR, in MLC cells treated with CA (data not shown).

The proliferative and neuroendocrine-like activation of cholangiocytes contributes to ductular reaction in cholestatic liver disease. To determine whether miR-200c regulates cholangiocyte proliferation, MLC cells were transfected with miR-200c-expressing plasmids and then treated with CA. CA-treatment increased the proliferation of MLC cells as measured by BrdU incorporation, which was ameliorated by miR-200c overexpression (Fig. 1D), indicating that miR-200c confines the proliferation potential of cholangiocytes. CA-treatment also increased expression of the pro-proliferative IL-6 in MLC cells, which was augmented by the miR-200c inhibitor (anti-miR-200c) but prevented by miR-200c overexpression (Fig. 1E and Supporting Fig. 1F). A similar role of miR-200c in regulation of IL-6 expression was found in TCA-treated MLC cells (Supporting Fig. 1G). Taken together, these results suggest that cholangiocyte proliferation induced by BA-exposure is at least contributed by inhibition of miR-200c expression and activation of IL-6 expression.

Loss of miR-200c aggravates the development of biliary fibrosis in mice

BDL leads to ductal proliferative responses and rapid establishment of periportal fibrosis. Body and liver weights were similar between wild type (WT) and Mir200c−/− mice before and after surgery (Supporting Fig. 2A, B). H&E, Masson Trichrome, and IHC of PCNA and KRT19 staining, did not identify differences in the liver between WT-sham and Mir200c−/−-sham mice (Supporting Fig. 3A). The levels of ALT, AST, DBIL, and BAs were comparably elevated in the serum of WT-BDL and Mir200c−/−-BDL mice compared to sham groups, although the BA level was lower in Mir200c−/−-BDL vs. WT-BDL mice (Supporting Fig. 3B). As expected, biliary fibrosis was aggravated in Mir200c−/−-BDL vs. WT-BDL mice, as revealed by H&E, Masson Trichrome (Fig. 2A and Supporting Fig. 4A), and Sirius Red staining (Supporting Fig. 4B). Bile infarct areas and PCNA- and KRT19-positive cells were also markedly increased in Mir200c−/−-BDL vs. WT-BDL mice (Fig. 2A and Supporting Fig. 4A).

Fig. 2. miR-200c-deficiency exacerbates cholestatic liver fibrosis in mice.

Fig. 2

Open in a new tab

A, B Representative images of H&E, Masson Trichrome, and IHC of PCNA and KRT19 staining of liver sections in BDL (A) and DDC (B) models. WT and Mir200c−/− mice were subjected to sham or BDL for 1 week (n = 10 mice/group) or fed a chow or DDC diet for one month (n = 7 mice/group). C, D qPCR of gene expression in livers from sham- or BDL-operated mice. Data are shown as mean ± SEM (n = 10 mice/group). *P < 0.05 & **P < 0.01 vs. WT-sham; #P < 0.05 & ##P < 0.01 vs. WT-BDL. E Measurement of liver and serum MPO activity, as well as serum levels of IL-6 and TNF. Data are shown as mean ± SEM (n = 10 mice/group). **P < 0.01 vs. WT-sham; #P < 0.05 & ##P < 0.01 vs. WT-BDL.

DDC-feeding results in a reactive phenotype of cholangiocytes, renders bile duct injury, and induces biliary type liver fibrosis. Body and liver weights, liver histology, and hepatic expression of PCNA and KRT19 remained comparable between WT-chow and Mir200c−/−-chow mice; DDC-feeding similarly increased liver weight and liver/body weight ratio in both genotypes (Supporting Figs. 5 and 6A). The serum levels of AST, ALT, and DBIL showed similar increases between WT-DDC and Mir200c−/−-DDC mice; however, DDC-feeding reduced the serum BA level in Mir200c−/− mice (Supporting Fig. 6B). Consistent with the BDL model, biliary proliferation and periductular fibrosis were aggravated in Mir200c−/−-DDC vs. WT-DDC mice, as indicated by the IHC staining of PCNA and KRT19, and the Masson Trichrome/Sirius Red staining, respectively (Fig. 2B and Supporting Fig. 7A and B). The severity of intrahepatic bile infarct was also increased in Mir200c−/−-DDC vs. WT-DDC mice (Supporting Fig. 7A).

Because the phenotypic changes were consistent in Mir200c−/−-BDL and Mir200c−/−-DDC mice, subsequent studies were focused on the BDL model. Loss of miR-200c increased expression of multiple genes related to inflammation, including Il6, Il1b, Nlrp3, and Tnf) in BDL mice (Fig. 2C). The expression levels of adhesion molecules (Icam1, Vcam1), a chemokine (Ccl2, alias Mcp-1), a neutrophil marker (Ly6g), chemoattractants for monocytes and/or neutrophils (Ccl3, alias Mip1a; Ccl4, alias Mip1b), a macrophage marker (Adgre1, alias F4/80), and a monocyte linage marker (Cd68) were analyzed. Except Tnf, hepatic expression levels of these genes were all induced by BDL compared to sham, which was further increased by miR-200c-deficiency (Fig. 2D). Similarly, liver and serum myeloperoxidase (MPO) activity, as a marker of neutrophil infiltration36, and serum IL-6 levels were further elevated in Mir200c−/−-BDL vs. WT-BDL mice. On the other hand, the level of serum TNF was similarly induced in Mir200c−/−-BDL and WT-BDL mice (Fig. 2E). Thus, these results suggest that miR-200c-deficiency exacerbated cholestatic liver fibrosis by activating genes associated with cholangiocyte proliferation, fibrogenesis, and inflammation.

SESN1 functions downstream of miR-200c to regulate IL-6-mediated cholangiocyte proliferation

To better understand the underlying mechanisms by which miR-200c protects against cholestatic liver fibrosis, it is critical to identify new miR-200c target genes. We used multiple online prediction tools (TargetScan, miRDB, PicTar, RNA22, and miRanda) to increase the stringency. A conserved seed match region of miR-200c was found in the 3’-UTR of SESN1 mRNA in both humans (hSESN1) and mice (mSESN1) (Fig. 3A left). Based on the binding free energy, the probability of miR-200c binding to the 3’-UTR of SESN1 mRNA in humans (−19.7 kcal/mol) and mice (−23.9 kcal/mol) was 98 and 95%, respectively, indicating a high likelihood of binding (Supporting Figs. 8 and 9). As expected, miR-200c overexpression reduced expression of SESN1 at both protein and mRNA levels in MLC cells and HuCCT-1 cells (Fig. 3A right and Supporting Fig. 10A). We constructed a luciferase reporter containing hSESN1 3’-UTR region for further validation (Supporting Fig. 10B). MiR-200c repressed the activity of hSESN1 3’-UTR reporter in a dose-dependent manner in 293 T and MLC cells (Fig. 3B left), whereas the effect of miR-200c was abolished when its binding site was mutated (Fig. 3B right). In contrast, miR-200c did not affect mRNA levels of other predicted targets, such as Moesin (Msn) (Supporting Fig. 10C).

Fig. 3. Identification of SESN1 as a miR-200c target gene.

Fig. 3

Open in a new tab

A Left: Diagram showing the binding sites of miR-200c in the 3’-UTR of SESN1 mRNA in humans (hSESN1) and mice (mSESN1). Right: WB of the expression level of SESN1. MLC and HuCCT-1 cells were transfected with control (con) or miR-200c plasmid for 48 h and total proteins were isolated for the assay. B Left: Transient transfection to determine luciferase reporter activity of SESN1 3’-UTR regulated by miR-200c. Right: Mutagenesis assays. A mutant luciferase reporter construct of SESN1 3’-UTR, as shown in A, was generated and used for transient transfection. Data are shown as mean ± SEM. *P < 0.05 & **P < 0.01 vs. control miRNA (−). C WB of indicated proteins in MLC cells treated with CA of different concentrations for 24 h (left), CA (100 µM) for different time (left), or different BAs (100 µM) for 24 h (right). D Left: WB of SESN1 protein in MLC cells transfected with the miR-200c inhibitor (anti-miR) in the presence or absence of CA treatment. Right: WB of SESN1 protein in WT and Mir200c−/− livers from the BDL or DDC model. E BrdU incorporation to determine cell proliferation. Left: MLC cells were transfected with control (−) or shSESN1 (+) shRNA for 24 h, followed by the treatment with DMSO or CA for 48 h in the presence of BrdU. Middle: MLC cells were transfected with the empty vector (−) or SESN1 plasmid (+) for 24 h. Then, the cells were treated with DMSO or CA for 48 h in the presence of BrdU. Right: WB of indicated proteins in MLC cells after SESN1 overexpression. Data are shown as mean ± SEM. **P < 0.01 vs. DMSO; #P < 0.05 & ##P < 0.01 vs. (−)-CA. F ELISA of IL-6 secretion. Left: MLC cells were treated as in (E, left). Right: MLC cells were treated as in (E, middle). Data are shown as mean ± SEM. *P < 0.05 & **P < 0.01 vs. DMSO; #P < 0.05 & ##P < 0.01 vs. (−)-CA.

As CA decreased the expression level of miR-200c (Fig. 1B), we asked whether it could induce SESN1 expression. Indeed, western blot showed that CA increased expression of SESN1 in a dose- and time-dependent manner but had no effect on MSN (Fig. 3C left). Among the several BAs, TCA exhibited the highest potency to induce expression of SESN1 (Fig. 3C right). CA induced SESN1 expression but failed to increase its expression in the presence of the miR-200c inhibitor (anti-miR-200c), suggesting that CA-induction of SESN1 expression was mediated at least through miR-200c (Fig. 3D left). Hepatic expression of SESN1 was induced by BDL and DDC in both WT and Mir200c−/− mice. Also, miR-200c-deficiency potentiated hepatic expression of SESN1 in both sham- and BDL-operated mice, as well as in both chow- and DDC-fed mice (Fig. 3D right). These results were consistent with our in vitro results demonstrating that SESN1 was a direct target gene of miR-200c.

We interrogated whether SESN1 promoted cholangiocyte proliferation and IL-6 production. In the presence of CA, knockdown of SESN1 (Supporting Fig. 10D) inhibited BrdU incorporation (Fig. 3E left) and IL-6 production (Fig. 3F left), while overexpression of SESN1 potentiated CA-induced BrdU incorporation (Fig. 3E middle) and IL-6 production (Fig. 3F right). Further, SESN1 overexpression increased expression of KRT19 (Fig. 3E right). These results suggested that SESN1 facilitated IL-6-mediated cholangiocyte proliferation.

Sesn1-deficiency prevents the development of cholestatic liver fibrosis in mice

No significant changes were observed in liver histology, biliary proliferation, and liver fibrosis in Sesn1−/−-sham vs. Sesn1+/+-sham mice (Supporting Fig. 11A). Serum levels of ALT, AST, bilirubin, and BAs did not show a significant reduction in Sesn1−/−-BDL vs. Sesn1+/+-BDL mice (Supporting Fig. 11B). H&E, Masson Trichrome, and Sirius Red staining revealed a marked reduction in periductular fibrosis in Sesn1−/−-BDL vs. Sesn1+/+-BDL mice; intrahepatic proliferation and biliary hyperplasia were also ameliorated, as revealed by IHC of PCNA and KRT19 (Fig. 4A and Supporting Fig. 12A, B). Consistently, hepatic expression levels of genes, including a progenitor cell marker (Sox9), a liver fibrosis marker (Acta2), and an inflammation marker (Il6), were decreased in Sesn1−/−-BDL vs. Sesn1+/+-BDL mice (Fig. 4B). In contrast, expression of many genes involved in BA metabolism, fibrosis, and inflammation remained at comparable levels between Sesn1−/−-BDL and Sesn1+/+-BDL mice (Supporting Fig. 13).

Fig. 4. Sesn1-deficiency alleviates cholestatic liver fibrosis.

Fig. 4

Open in a new tab

A Representative images of H&E, Masson Trichrome, and IHC of PCNA and KRT19 staining of liver sections in Sesn1+/+ and Sesn1−/− mice subjected to BDL for 1 week (n = 10 mice/group). B qPCR of gene expression in livers from Sesn1+/+ and Sesn1−/− mice subjected to sham or BDL for 1 week. C, D WB of proteins in the livers from the indicated mice 1 week post-sham or -BDL surgery. E MPO activity in the liver and serum and levels of IL-6 and TNF in the serum from mice in B. All data are shown as mean ± SEM (n = 10 mice/group). **P < 0.01 vs. Sesn1+/+-sham; #P < 0.05 & ##P < 0.01 vs. Sesn1+/+−BDL.

Corresponding to the induction of mRNAs, ACTA2 and SOX9 proteins in the liver were highly induced by BDL in Sesn1+/+ mice; however, the induction was diminished by Sesn1-deficiency (Fig. 4C left). Examination of several signaling pathways revealed a striking elevation of p-AKT protein in Sesn1+/+-BDL, which was greatly dampened in Sesn1−/−-BDL livers (Fig. 4C left and Fig. 4D left), suggesting that SESN1 contributed to AKT activation in cholestasis. Hepatic expression of SESN1, ACTA2, SOX9, and p-AKT proteins were induced by BDL, which was further potentiated by miR-200c deficiency (Fig. 3C right). On the other hand, the levels of p-ERK1/2, p-JNK1/2, and p-p38 proteins did not noticeably change in Sesn1−/−-BDL vs. Sesn1+/+-BDL livers (Fig. 4D left). In contrast to enhancement of p-AKT expression (Fig. 3C right), p-ERK1/2, p-JNK1/2, and p-p38 proteins in the liver were moderately reduced in Mir200c−/−-BDL vs. WT-BDL mice (Fig. 4D right). These results demonstrated that Sesn1-deficiency diminished AKT activation to protect against the intrahepatic proliferation and biliary hyperplasia in cholestasis. Moreover, MPO activities in the liver and serum were reduced in Sesn1−/−-BDL vs. Sesn1+/+-BDL mice (Fig. 4E). The serum level of IL-6 but not TNF was significantly attenuated by Sesn1-deficiency in BDL-operated mice (Fig. 4E). Therefore, the above results suggested that SESN1 contributed to AKT activation and IL-6 expression to regulate the development of cholestatic liver injury.

Rescuing expression of miR-200c alleviates biliary fibrosis in Mir200c−/−-BDL mice

We conducted rescue experiments in Mir200c−/− mice transduced with AAV8-miR-200c or AAV8- control (con) to further confirm the role of miR-200c in BDL-induced cholestatic liver fibrosis (Supporting Fig. 14A). H&E and Masson Trichrome staining showed remarkable attenuation of periportal fibrosis in miR-200c-BDL vs. con-BDL mice (Fig. 5A). The reduced liver injury was accompanied by decreased serum levels of ALT, AST, and bilirubin, while the serum level of BAs did not significantly change (Fig. 5B). We also checked hepatic mRNA expression of the major regulators of the BA biosynthesis pathways. Expression of Cyp7a1 and Cyp27a1, the rate-limiting enzyme of BA synthesis in the classic pathway and the alternative pathway respectively, had no significant difference between miR-200c-BDL and con-BDL mice. Interestingly, gene expression of another BA synthesis enzyme, Cyp8b1, was reduced in miR-200c-BDL vs. con-BDL mice. Expression of Bsep, a gene for the hepatic canalicular bile salt export pump, was also moderately reduced in miR-200c-BDL mice. The mRNA levels of Ntcp, Fxr, and Oatp1b2 had no significant changes; however, expression of Shp, a FXR target gene, was upregulated in miR-200c-BDL vs. con-BDL mice (Supporting Fig. 14B).

Fig. 5. Reconstitution of miR-200c in Mir200c−/− mice prevents the progression of cholestatic liver fibrosis.

Fig. 5

Open in a new tab

A Representative images of H&E and Masson Trichrome staining of liver sections. Mir200c−/− mice were transduced with AAV8-con (control) or AAV8-miR-200c (overexpression) viruses via tail vein injection for one month, followed by sham or BDL for 1 week (n = 5 mice/group). B, C, and D Levels of ALT, AST, TBIL, DBIL, and BAs in the serum (B), as well as qPCR of gene expression (C) and WB of protein expression (D) in the livers of mice from (A). All data are shown as mean ± SEM (n = 5 mice/group). *P < 0.05 &**P < 0.01 vs. AAV8-con.

The mRNA levels of liver fibrosis markers (Acta2, Col1a1, Col3a1, and Timp1), cholangiocyte proliferation markers (Krt7 and Krt19), inflammation markers (Il6 and Il1b), and the progenitor cell marker (Sox9) were markedly decreased in miR-200c-BDL mice compared to con-BDL mice. Expression of Sesn1 mRNA was also decreased in miR-200c-rescued mice (Fig. 5C). Expression of SESN1, ACTA2, SOX9, and p-AKT proteins were decreased in miR-200c-BDL mice vs. con-BDL mice (Fig. 5D). Taken together, these results demonstrated that miR-200c was protective in cholestatic liver fibrosis.

Expression of miR-200c and SESN1 is dysregulated in human liver diseases

PSC and PBC, the most common immune-mediated chronic cholestatic liver diseases, are pathologically manifested by ductular reaction and periportal fibrosis. Despite the insignificance, the expression level of miR-200c seemed to be elevated in PSC but not PBC compared to normal livers (Fig. 6A). Congenital hepatic fibrosis (CHF) is a rare developmental disorder characterized by severe periportal fibrosis and proliferation of interlobular bile ducts. Expression of MiR-200c was significantly and remarkably increased in CHF livers (Fig. 6B). We divided the normal, PSC, and PBC liver specimens into two groups based on the relative expression of miR-200c vs. the normal controls: miR-200c high and miR-200c low. SESN1 proteins were noticeably reduced in both the PSC and PBC liver specimens in which the expression level of miR-200c was high (Fig. 6C upper). Increased expression of SESN1 proteins was observed in both the PSC and PBC liver specimens in which the expression level of miR-200c was low (Fig. 6C lower). These demonstrated a negative correlation between the expression levels of SESN1 and miR-200c in cholestatic liver diseases. Biliary cellular senescence is an important pathogenic mechanism in PSC37,38. The expression level of miR-200c in the PSC livers negatively correlated with that of IL-6 but not CDKN2A, a cell senescence marker, suggesting the possible disassociation between miR-200c expression and biliary senescence (Fig. 6D).

Fig. 6. The expression level of SESN1 negatively correlates with that of miR-200c in human cholestatic liver diseases.

Fig. 6

Open in a new tab

A, B qPCR of miR-200c expression in human liver specimens. **P < 0.01 vs. normal controls. C Human liver specimens were divided into two groups, miR-200c high and miR-200c low, based on the expression level of miR-200c in disease livers vs. normal controls. Expression of SESN1 protein was determined by WB. D Pearson correlation of expression of miR-200c, IL-6, and CDKN2A mRNAs. Gene expression was determined by qPCR and normalized to normal controls. The relative fold change was used to plot the correlation. E A schematic showing that miR-200c inhibits cholestatic liver fibrosis via targeting SESN1 and inhibiting the IL-6/AKT feedback loop.

Discussion

This study is designed to identify the contribution of miRNAs to cholestatic liver diseases. NcRNAs are involved in a wide range of biological functions and processes by regulating diverse modes of molecular feedback and pathways12,39–41. MiR-200c is a multi-functional regulator in various biological events, such as epithelial-mesenchymal transition (EMT), apoptosis, and cell senescence42,43. During cholestasis, the neuroendocrine-like property and proliferative capacity of cholangiocytes are activated to aggravate the development of biliary liver fibrosis. In this study, we unravel a critical function of miR-200c in governing the homeostasis of cholangiocytes. We demonstrate that miR-200c/SESN1 axis acts upstream of the IL-6/AKT feedback loop to regulate IL-6 production and AKT activation, contributing to cholangiocyte activation and biliary fibrosis (Fig. 6E).

We find that SESN1 is a novel downstream target gene of miR-200c. SESN1 mediates the effect of miR-200c on the proliferative and neuroendocrine-like capacity (of producing the mitogenic IL-6) of cholangiocytes and engages in the pathogenesis of liver fibrosis. SESN1 has been shown to regulate cellular proliferation44. Knockdown of SESN1 expression significantly inhibits cell proliferation and accelerates cell senescence in human embryonic fibroblasts18. In line with this, we find that SESN1 facilitates proliferation in CA-treated cholangiocytes (Fig. 3E) and in BDL-operated mouse livers (Fig. 4A). To the best of our knowledge, we are the first group to provide evidence for the participation of SESN1 in cholangiocyte proliferation and the pathogenesis of cholestatic liver fibrosis. Although miR-200c regulates expression of SESN1, our correlation analysis suggests that miR-200c might not associate with biliary senescence, opposing to a previous report showing miR-200c induces senescence in human umbilical vein endothelial cells and possibly due to cell specificity45.

Our previous study found that hepatic expression of miR-200c was increased in BDL-operated mice, revealed by bulk RNA-sequencing22. In the bulk liver, the expression level of miR-200c can be determined by cell types, as well as pathology or disease types (Fig. 6). Moreover, the disease severity may vary a lot individually, thus differentially affect expression of miR-200c. In terms of the individual cell types, expression of miR-200c was elevated moderately in hepatocytes but decreased dramatically in cholangiocytes by BDL (Fig. 1). Cholangiocytes constitute 3~5% of the liver cell population46, whereas hepatocytes make up 70–85% of the liver mass47. Although the expression level of miR-200c in hepatocytes was much lower than other liver cell types, hepatocytes can be an important source of hepatic miR-200c and miR-200c in hepatocytes may be essential in disease pathogenesis. Indeed, miR-200c-deficiency reduces methionine- and choline-deficient (MCD) diet-induced hepatic steatosis20. Tissue-specific Mir200c−/− mice are beneficial to further dissect the cell-specific contribution of miR-200c in the pathophysiology of cholestatic and other liver diseases.

Liver fibrosis is characterized by excessive extracellular matrix deposition and HSCs differentiation into myofibroblast-like cells48. ACTA2 is one of the most reliable markers of HSC activation49. Expression of ACTA2 is markedly increased in Mir200c−/−-BDL vs. WT-BDL mice but decreased in Sesn1−/−-BDL vs. Sesn1+/+-BDL mice (Fig. 4C). These results suggest that miR-200c also regulates HSCs activation in cholestatic liver fibrosis. The role of miR-200c/SESN1 axis will be further elucidated in HSCs.

Hepatic inflammation is an important feature of cholestatic liver diseases in both humans and experimental animals50. Studies in BDL-operated mice have demonstrated the crucial role of neutrophils in cholestatic liver injury51,52. As demonstrated in this report, the expression level of the neutrophil marker Ly6g and the activity of MPO (the most abundantly expressed in neutrophils) are increased in response to BDL, which is further increased in Mir200c−/−-BDL mice. It is likely that miR-200c also regulates the function of neutrophils during cholestasis, yet expression of miR-200c in neutrophils is unknown. It seems that KCs do not play a role in cholestatic liver injury, as depletion of KCs does not reduce liver injury in BDL-operated mice53. Also, there were no differences between WT and Mir200c−/− mice after BDL in terms of macrophage marker expression (Fig. 2D).

The PI3K/AKT pathway plays a pivotal role in cholangiocyte proliferation54. Activation of AKT is an early event in BAs-mediated cholangiocyte proliferation and secretion55. IL-6 triggers the PI3K/AKT pathway that protects against apoptosis and enhances proliferation56. AKT increases IL-6 production and thus constitutes a feedforward loop with IL-69,10. Our study finds that the IL-6/AKT loop is activated by BDL, which is boosted by miR-200c-deletion and diminished by SESN1-deletion. This demonstrates that the IL-6/AKT loop can be regulated by miR-200c/SESN1 during cholestasis. Of note, IL-6, along with IL-8 and CCL-5, has been revealed to be a direct target of miR-200c57. We do not exclude other mediators downstream of miR-200c in cholestasis and biliary liver fibrosis, but IL-6 can be regarded as a critical contributor to the hepatic damage in miR-200c-deficient BDL mice, given its prominent role in cholangiocyte proliferation and inflammatory responses4,58. MiR-200c inhibits the IL-6/AKT loop not only through SESN1-mediated inhibition of AKT but also by directly targeting IL-6. It is possible that AKT is not the only mediator of SESN1 to induce IL-6 expression. Indeed, sestrins also activate Nrf2 to induce IL-6 expression59. The molecular mechanism as to how SESN1 activates AKT needs further investigation. As a family of highly conserved stress-inducible proteins, sestrins regulate antioxidant defense and autophagy60. In this study, the function of SESN1 is prominent in the presence of cholestasis because SESN1 is induced by BAs in vitro and during cholestasis. Without these, neither cell proliferation nor IL-6 expression is affected by SESN1. In contrast to a previous report that SESN1/2/3 interact and inhibit the activation of JNK in Western diet-induced hepatic lipotoxicity61, we find that during cholestasis, SESN1 does not regulate the activity of JNK, ERK, and p38 (Fig. 4D), which is possibly due to distinct etiologies and cell-specific responses.

In summary, our study reveals a novel function of miR-200c as an anti-fibrotic regulator of cholestatic liver fibrosis. In cholestasis, accumulated BAs result in the marked reduction of miR-200c and the subsequent increase of SESN1 in cholangiocytes, which contributes to the activation of the IL-6/AKT loop and increases ductular reaction, biliary hyperplasia, and biliary fibrosis (Fig. 6E). Our findings provide novel mechanistic insights into the role of a miRNA in the pathophysiology of cholestatic liver diseases and suggest that miR-200c may be a new therapeutic target for cholangiopathies.

Supplementary information

Supporting Information (1,022.2KB, pdf)

Acknowledgements

We thank Dr. Meenakshisundaram Ananthanarayanan (Yale University) for cholangiocyte-derived MLC and MSC cells. M.T. was supported by an American Heart Association postdoctoral fellowship (18POST33960183). D.S. is supported by NIH R01AA026322. J.W. is supported by NIH P30DK097948 through the Cleveland Digestive Diseases Research Core Center (DDRCC) Pilot/Feasibility program (Pilot, to J.W.) and NIH K01AA029474 (to J.W.). J.W. was also supported by NIH P50AA024333, R01AA027456, and U01AA026938 (all to Laura E. Nagy, Cleveland Clinic).

Author contributions

Y.S. designed and performed experiments and drafted the manuscript. M.T., L.W., and D.S. provided technical support. J.W. designed and performed experiments and wrote the manuscript.

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare no competing interests.

Ethics Approval and consent to participate

This study is not research involving human subjects and does not require patient-informed consent, which was determined by the Institutional Review Board (IRB) at the University of Connecticut. The animal protocol was approved by the Institutional Animal Care and Use Committee (IACUC) and the use of viruses was approved by the Institutional Biosafety Committee (IBC) at the University of Connecticut.

Footnotes

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

The online version contains supplementary material available at 10.1038/s41374-021-00710-6.

References

  • 1.Trauner M, Fuchs CD, Halilbasic E, Paumgartner G. New therapeutic concepts in bile acid transport and signaling for management of cholestasis. Hepatology. 2017;65:1393–1404. doi: 10.1002/hep.28991. [DOI] [PubMed] [Google Scholar]
  • 2.Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr. Physiol. 2013;3:1473–1492. doi: 10.1002/cphy.c120035. [DOI] [PubMed] [Google Scholar]
  • 3.O’Hara SP, Tabibian JH, Splinter PL, LaRusso NF. The dynamic biliary epithelia: molecules, pathways, and disease. J. Hepatol. 2013;58:575–582. doi: 10.1016/j.jhep.2012.10.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Yokomuro S, et al. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology. 2000;32:26–35. doi: 10.1053/jhep.2000.8535. [DOI] [PubMed] [Google Scholar]
  • 5.Cressman DE, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science. 1996;274:1379–1383. doi: 10.1126/science.274.5291.1379. [DOI] [PubMed] [Google Scholar]
  • 6.Park J, Gores GJ, Patel T. Lipopolysaccharide induces cholangiocyte proliferation via an interleukin-6-mediated activation of p44/p42 mitogen-activated protein kinase. Hepatology. 1999;29:1037–1043. doi: 10.1002/hep.510290423. [DOI] [PubMed] [Google Scholar]
  • 7.Heinrich PC, et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003;374:1–20. doi: 10.1042/bj20030407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene. 2001;20:5991–6000. doi: 10.1038/sj.onc.1204833. [DOI] [PubMed] [Google Scholar]
  • 9.Hou CH, Fong YC, Tang CH. HMGB-1 induces IL-6 production in human synovial fibroblasts through c-Src, Akt and NF-kappaB pathways. J. Cell Physiol. 2011;226:2006–2015. doi: 10.1002/jcp.22541. [DOI] [PubMed] [Google Scholar]
  • 10.Tang L, et al. Suppression of sirtuin-1 increases IL-6 expression by activation of the Akt pathway during allergic asthma. Cell Physiol. Biochem. 2017;43:1950–1960. doi: 10.1159/000484119. [DOI] [PubMed] [Google Scholar]
  • 11.Gu FM, et al. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Mol Cancer. 2011;10:150. doi: 10.1186/1476-4598-10-150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Wu J, Nagy LE, Liangpunsakul S, Wang L. Non-coding RNA crosstalk with nuclear receptors in liver disease. Biochim. Biophys. Acta Mol. Basis Dis. 2021;1867:166083. doi: 10.1016/j.bbadis.2021.166083. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kennedy LL, et al. Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice. Lab. Invest. 2016;96:1256–1267. doi: 10.1038/labinvest.2016.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Murakami Y, et al. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS ONE. 2011;6:e16081. doi: 10.1371/journal.pone.0016081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Feng YY, et al. Aberrant hepatic microRNA expression in nonalcoholic fatty liver disease. Cell Physiol. Biochem. 2014;34:1983–1997. doi: 10.1159/000366394. [DOI] [PubMed] [Google Scholar]
  • 16.Xiao Y, et al. Up-regulation of miR-200b in biliary atresia patients accelerates proliferation and migration of hepatic stallate cells by activating PI3K/Akt signaling. Cell Signal. 2014;26:925–932. doi: 10.1016/j.cellsig.2014.01.003. [DOI] [PubMed] [Google Scholar]
  • 17.Sun X, et al. Participation of miR-200a in TGF-beta1-mediated hepatic stellate cell activation. Mol. Cell Biochem. 2014;388:11–23. doi: 10.1007/s11010-013-1895-0. [DOI] [PubMed] [Google Scholar]
  • 18.Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science. 2004;304:596–600. doi: 10.1126/science.1095569. [DOI] [PubMed] [Google Scholar]
  • 19.Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell. 2008;134:451–460. doi: 10.1016/j.cell.2008.06.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Tran M, Lee SM, Shin DJ, Wang L. Loss of miR-141/200c ameliorates hepatic steatosis and inflammation by reprogramming multiple signaling pathways in NASH. JCI Insight. 2017;2:e96094. doi: 10.1172/jci.insight.96094. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Zhang Y, et al. E2F1 is a novel fibrogenic gene that regulates cholestatic liver fibrosis through the Egr-1/SHP/EID1 network. Hepatology. 2014;60:919–930. doi: 10.1002/hep.27121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Zhang L, Yang Z, Huang W, Wu J. H19 potentiates let-7 family expression through reducing PTBP1 binding to their precursors in cholestasis. Cell Death Dis. 2019;10:168. doi: 10.1038/s41419-019-1423-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Lee SM, et al. Small heterodimer partner/neuronal PAS domain protein 2 axis regulates the oscillation of liver lipid metabolism. Hepatology. 2015;61:497–505. doi: 10.1002/hep.27437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Song Y, et al. H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of epithelial cell adhesion molecule. Hepatology. 2017;66:1183–1196. doi: 10.1002/hep.29209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Zhang Y, et al. Bcl2 is a critical regulator of bile acid homeostasis by dictating Shp and lncRNA H19 function. Sci. Rep. 2016;6:20559. doi: 10.1038/srep20559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Werner M, et al. All-In-One: Advanced preparation of Human Parenchymal and Non-Parenchymal Liver Cells. PLoS ONE. 2015;10:e0138655. doi: 10.1371/journal.pone.0138655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Wang Y, et al. The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice. Hepatology. 2017;65:2005–2018. doi: 10.1002/hep.29076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Wu J, et al. Loss of PDK4 switches the hepatic NF-kappaB/TNF pathway from pro-survival to pro-apoptosis. Hepatology. 2018;68:1111–1124. doi: 10.1002/hep.29902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Zhang Y, et al. Effect of bile duct ligation on bile acid composition in mouse serum and liver. Liver Int. 2012;32:58–69. doi: 10.1111/j.1478-3231.2011.02662.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.de Aguiar Vallim TQ, Tarling EJ, Edwards PA. Pleiotropic roles of bile acids in metabolism. Cell Metab. 2013;17:657–669. doi: 10.1016/j.cmet.2013.03.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Hanafi NI, Mohamed AS, Sheikh Abdul Kadir SH, Othman MHD. Overview of bile acids signaling and perspective on the signal of ursodeoxycholic acid, the most hydrophilic bile acid, in the heart. Biomolecules. 2018;8:159. doi: 10.3390/biom8040159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Monte MJ, Marin JJ, Antelo A, Vazquez-Tato J. Bile acids: chemistry, physiology, and pathophysiology. World J. Gastroenterol. 2009;15:804–816. doi: 10.3748/wjg.15.804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Fickert P, Wagner M. Biliary bile acids in hepatobiliary injury—What is the link? J. Hepatol. 2017;67:619–631. doi: 10.1016/j.jhep.2017.04.026. [DOI] [PubMed] [Google Scholar]
  • 34.Benedetti A, et al. Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver. Hepatology. 1997;26:9–21. doi: 10.1002/hep.510260102. [DOI] [PubMed] [Google Scholar]
  • 35.Kolesnikoff N, et al. Specificity protein 1 (Sp1) maintains basal epithelial expression of the miR-200 family: implications for epithelial-mesenchymal transition. J. Biol. Chem. 2014;289:11194–11205. doi: 10.1074/jbc.M113.529172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Pulli B, et al. Measuring myeloperoxidase activity in biological samples. PLoS ONE. 2013;8:e67976. doi: 10.1371/journal.pone.0067976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Tabibian JH, O’Hara SP, Splinter PL, Trussoni CE, LaRusso NF. Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis. Hepatology. 2014;59:2263–2275. doi: 10.1002/hep.26993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Meng L, et al. Functional role of cellular senescence in biliary injury. Am. J. Pathol. 2015;185:602–609. doi: 10.1016/j.ajpath.2014.10.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Willeit P, Skroblin P, Kiechl S, Fernandez-Hernando C, Mayr M. Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease? Eur. Heart. J. 2016;37:3260–3266. doi: 10.1093/eurheartj/ehw146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Glaser S, et al. Secretin stimulates biliary cell proliferation by regulating expression of microRNA 125b and microRNA let7a in mice. Gastroenterology. 2014;146:1795–1808.e1712. doi: 10.1053/j.gastro.2014.02.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Szabo G, Bala S. MicroRNAs in liver disease. Nat. Rev. Gastroenterol. Hepatol. 2013;10:542–552. doi: 10.1038/nrgastro.2013.87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Magenta A, Ciarapica R, Capogrossi MC. The emerging role of miR-200 family in cardiovascular diseases. Circ. Res. 2017;120:1399–1402. doi: 10.1161/CIRCRESAHA.116.310274. [DOI] [PubMed] [Google Scholar]
  • 43.Humphries B, Yang C. The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. Oncotarget. 2015;6:6472–6498. doi: 10.18632/oncotarget.3052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Cai B, et al. MiR-16-5p targets SESN1 to regulate the p53 signaling pathway, affecting myoblast proliferation and apoptosis, and is involved in myoblast differentiation. Cell Death Dis. 2018;9:367. doi: 10.1038/s41419-018-0403-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Magenta A, et al. miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ. 2011;18:1628–1639. doi: 10.1038/cdd.2011.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Esteller A. Physiology of bile secretion. World J. Gastroenterol. 2008;14:5641–5649. doi: 10.3748/wjg.14.5641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Stanger BZ. Cellular homeostasis and repair in the mammalian liver. Annu. Rev. Physiol. 2015;77:179–200. doi: 10.1146/annurev-physiol-021113-170255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Chiang JY. Bile acids: regulation of synthesis. J. Lipid Res. 2009;50:1955–1966. doi: 10.1194/jlr.R900010-JLR200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Yang Z, Koehler AN, Wang L. A novel small molecule activator of nuclear receptor SHP inhibits HCC cell migration via suppressing Ccl2. Mol Cancer Ther. 2016;15:2294–2301. doi: 10.1158/1535-7163.MCT-16-0153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Saito JM, Maher JJ. Bile duct ligation in rats induces biliary expression of cytokine-induced neutrophil chemoattractant. Gastroenterology. 2000;118:1157–1168. doi: 10.1016/S0016-5085(00)70369-6. [DOI] [PubMed] [Google Scholar]
  • 51.Gujral JS, Farhood A, Bajt ML, Jaeschke H. Neutrophils aggravate acute liver injury during obstructive cholestasis in bile duct-ligated mice. Hepatology. 2003;38:355–363. doi: 10.1053/jhep.2003.50341. [DOI] [PubMed] [Google Scholar]
  • 52.Gujral JS, Liu J, Farhood A, Hinson JA, Jaeschke H. Functional importance of ICAM-1 in the mechanism of neutrophil-induced liver injury in bile duct-ligated mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2004;286:G499–G507. doi: 10.1152/ajpgi.00318.2003. [DOI] [PubMed] [Google Scholar]
  • 53.Gehring S, et al. Kupffer cells abrogate cholestatic liver injury in mice. Gastroenterology. 2006;130:810–822. doi: 10.1053/j.gastro.2005.11.015. [DOI] [PubMed] [Google Scholar]
  • 54.Glaser S, et al. Adrenergic receptor agonists prevent bile duct injury induced by adrenergic denervation by increased cAMP levels and activation of Akt. Am. J. Physiol. Gastrointest. Liver Physiol. 2006;290:G813–G826. doi: 10.1152/ajpgi.00306.2005. [DOI] [PubMed] [Google Scholar]
  • 55.Alpini G, et al. Bile acid depletion and repletion regulate cholangiocyte growth and secretion by a phosphatidylinositol 3-kinase-dependent pathway in rats. Gastroenterology. 2002;123:1226–1237. doi: 10.1053/gast.2002.36055. [DOI] [PubMed] [Google Scholar]
  • 56.Johnson C, et al. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl. Gastrointest. Cancer. 2012;1:58–70. doi: 10.3978/j.issn.2224-4778.2011.11.02. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Hong L, et al. MicroRNA-200c represses IL-6, IL-8, and CCL-5 expression and enhances osteogenic differentiation. PLoS ONE. 2016;11:e0160915. doi: 10.1371/journal.pone.0160915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Matsumoto K, Fujii H, Michalopoulos G, Fung JJ, Demetris AJ. Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro. Hepatology. 1994;20:376–382. doi: 10.1002/hep.1840200217. [DOI] [PubMed] [Google Scholar]
  • 59.Wruck CJ, et al. Nrf2 induces interleukin-6 (IL-6) expression via an antioxidant response element within the IL-6 promoter. J. Biol. Chem. 2011;286:4493–4499. doi: 10.1074/jbc.M110.162008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Cordani M, Donadelli M, Strippoli R, Bazhin AV, Sanchez-Alvarez M. Interplay between ROS and autophagy in cancer and aging: from molecular mechanisms to novel therapeutic approaches. Oxid. Med. Cell Longev. 2019;2019:8794612. doi: 10.1155/2019/8794612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Fang Z, et al. Sestrin proteins protect against lipotoxicity-induced oxidative stress in the liver via suppression of C-Jun N-terminal kinases. Cell Mol. Gastroenterol. Hepatol. 2021;12:921–942. doi: 10.1016/j.jcmgh.2021.04.015. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting Information (1,022.2KB, pdf)

Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Articles from Laboratory Investigation; a Journal of Technical Methods and Pathology are provided here courtesy of Nature Publishing Group

RESOURCES